Target species
Cats.
Indications for use, specifying the target species:
Active immunisation of cats aged 8 weeks and older against:
- Feline viral rhinotracheitis to reduce clinical signs.
- Calicivirus infection to reduce clinical signs.
- Feline panleucopenia to prevent mortality and clinical signs.
- Leukaemia to prevent persistent viraemia and clinical signs of the related disease.
Onsets of immunity:
Rhinotracheitis, calicivirus and panleucopenia components: one week after primary vaccination course.
Feline leukaemia component: 2 weeks after primary vaccination course.
Duration of immunity:
Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last re-vaccination.
Feline leukaemia component: 1 year after the last re-vaccination.
Contra-indications
None.
Special warnings for each target species
Vaccinate healthy animals only.
Special precautions for use in animals
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV positive cats is of no benefit.
Special precautions to be taken by the person administering the product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions
Cats:
Common (1 to 10 animals / 100 animals treated): Apathy, anorexia, and hyperthermia.1 Injection site reactions (pain, itching, oedema).2
Uncommon (1 to 10 animals / 1 000 animals treated): Hypersensitivity reaction.3
Very rare (1 animal / 10 000 animals treated,including isolated reports):Emesis.4
1 lasting usually for 1 or 2 days.
2 slight pain at palpation, itching or limited oedema disappearing within 1 or 2 weeks at most.
3 may require appropriate symptomatic treatment.
4 mostly within 24 to 48 hours.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder, or its local representative, or the national competent authority via the national reporting system. See also section “Contact details” of the package leaflet details.
Use during pregnancy, lactation or lay
Do not use during the whole pregnancy and lactation.
Interactions
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Boehringer Ingelheim non-adjuvanted vaccine against rabies
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
Subcutaneous route.
Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formatino. Visual appearance after reconstitution: slightly yellow suspension with presence of cell debris in suspension.
After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen), inject one dose of vaccine according to the following vaccination scheme:
Primary vaccination course:
- First injection from 8 weeks of age
- Second injection 3 to 4 weeks later
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9-12 weeks of age borne from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Revaccination:
- The first revaccination must be carried out for all components one year after the primary vaccination course,
- Subsequent revaccinations: Feline leukaemia component: every year. Rhinotracheitis, calicivirosis and panleucopenia components: at intervals of up to three years.
Overdose
No effect other than those already mentioned under Adverse reactions have been observed, except hyperthermia that may exceptionally last 5 days.